Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2015-03-03 |
Amag Pharmaceuticals (USA - MA) |
$ 201 million (€ 179.8 million) |
private placement |
|
|
Private placement |
2015-03-02 |
GenePOC (Canada) |
undisclosed |
financing round |
Debiopharm Diagnostics (Switzerland) Emerillon Capital (Canada) |
Infectious diseases - Diagnostic |
Financing round |
2015-03-02 |
Xencor (USA - CA) |
$122.9 million |
private placement |
|
Allergic diseases - Autoimmune diseases - Respiratory diseases - Cancer - Oncology |
Private placement |
2015-03-01 |
DiViNe consortium (Affilogic (France) Aquaporin (Denmark), GenIbet Biopharmaceuticals (Portugal) GSK (UK) iBET (Portugal) Merck KGaA (Germany) |
€5.8 million |
grant |
European Commission’s Horizon 2020 programme |
Infectious diseases - Technology - Services |
Grant |
2015-02-27 |
Celyad previously known as Cardio3 Biosciences (Belgium) |
€ 32 million |
private placement |
|
Cardiovascular diseases - Cancer - Oncology |
Private placement |
2015-02-27 |
Celldex Therapeutics (USA - NJ) |
$24.7 million |
private placement |
|
Cancer - Oncology |
Private placement |
2015-02-24 |
Prexton Therapeutics (Switzerland) |
€8.7 million ($10 million) |
series A financing round |
Sunstone Capital (Denmark) Ysios Capital (Spain) MS Ventures (Germany) |
CNS diseases - Neurodegenerative diseases |
Series A financing round |
2015-02-23 |
The University of Manchester (UK) Cobra Biologics (Sweden) |
£217 000 |
grant |
Innovate UK (UK) |
Technology - Services |
Grant |
2015-02-20 |
Neurovive Pharmaceutical (Sweden) |
SEK 65 million (€ 6.8 million) |
private placement |
|
Cardiovascular diseases |
Private placement |
2015-02-19 |
VolitionRx (Singapore) |
|
private placement |
|
Cancer - Oncology - Infectious diseases - Diagnostic |
Private placement |
2015-02-18 |
Horizon Discovery (UK) |
£1.67 million |
grant |
Innovate UK (UK) Biotechnology and Biological Sciences Research Council (BBSRC) (UK) |
Technology - Services |
Grant |
2015-02-17 |
Quantum Genomics (France) |
€11.2 million |
capital increase |
|
Cardiovascular diseases |
Capital increase |
2015-02-15 |
Poxel (France) |
€ 25 million |
IPO |
|
Metabolic diseases |
IPO |
2015-02-12 |
AC Immune (Switzerland) |
undisclosed |
grant |
The Michael J. Fox Foundation - MJFF (USA) |
Neurodegenerative diseases |
Grant |
2015-02-11 |
Bone Therapeutics (Belgium) |
€37 million |
IPO |
|
Bone diseases - Regenerative medicine |
IPO |
2015-02-11 |
Cortendo (Sweden) |
$26.4 million |
private placement |
RA Capital Management (USA - MA), New Enterprise Associates (NEA) (USA - MD), Broadfin Capital (USA - NY) HealthCap (Sweden) |
Rare diseases |
Private placement |
2015-02-11 |
Galapagos (Belgium) |
€1.6 million |
grant |
Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) |
Infectious diseases |
Grant |
2015-02-10 |
Inoviem Scientific (France) |
€ 0.5 million |
financing round |
Cap Innov’Est (France) |
Technology - Services |
Financing round |
2015-02-09 |
Innovacell (Austria) |
€ 3 million |
capital increase |
|
|
Capital increase |
2015-02-09 |
Melinta Therapeutics (USA - CT) |
$30 million |
loan |
Hercules Technology Growth Capital (USA - CA) |
Infectious diseases |
Loan |